Second-Line Uterotonics for Uterine Atony: A Randomized Controlled Trial

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Clinical Trials

Background:

• Uterine atony is a leading cause of postpartum hemorrhage.
• Second-line uterotonics are crucial for managing refractory uterine atony.
• Methylergonovine maleate and carboprost tromethamine are commonly used agents.

Purpose of the Study:

• To compare the efficacy of methylergonovine maleate and carboprost tromethamine as second-line uterotonics.
• To evaluate their effectiveness in patients undergoing cesarean delivery with oxytocin-refractory uterine atony.

Main Methods:

• A double-blind, randomized trial was conducted at two academic perinatal centers.
• 100 patients with refractory uterine atony received either methylergonovine or carboprost.
• Uterine tone was assessed using a 0-10 numeric rating scale 10 minutes post-administration.

Main Results:

• No significant difference in mean uterine tone scores was observed between methylergonovine (7.3±1.7) and carboprost (7.6±2.1) at 10 minutes (P =.76).
• Rates of additional uterotonic use (30.0% vs 34.0%) and quantitative blood loss (756 mL vs 708 mL) were similar between groups.
• No differences were detected in other interventions for uterine atony or hemorrhage.

Conclusions:

• Methylergonovine maleate and carboprost tromethamine demonstrate comparable efficacy in improving uterine tone for refractory uterine atony.
• Both agents are acceptable treatment options when initial oxytocin therapy fails.
• Further research may explore patient-specific factors influencing treatment response.